

We would like to express our deepest condolences to the victims, their families, and all those involved in the Noto Peninsula Earthquake of 2024. We extend our deepest sympathies to all those affected by the disaster.

Hisamitsu Pharmaceutical Co., Inc.

FY02/2024 Results

and Outlook for the FY02/2025

This presentation material contains information that constitutes forward-looking statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and actual results may differ from those in the forward-looking statements as a result of various factors including changes in material circumstances.

Hisamitsu Pharmaceutical Co., Inc.

Apr. 11th, 2024



Agenda

FY02/2024 Results

1. Looking back on the FY02/2024
2. Promotion of Sustainability
3. HX2025 Initiatives
4. Consolidated P&L
5. Sales Results by Region
6. Sales Results by Product
7. Trends of second-generation non-steroidal anti-inflammatory patch (Topical formulations) in Japan
8. Trends of non-steroidal anti-inflammatory drugs (Systemic formulations) in Japan
9. R&D Pipeline

Outlook for the FY02/2025

10. Forecast of Consolidated P&L
11. Forecast of Sales by Region
12. Forecast of Sales by Product
13. Forecast of Dividend
14. Reduction of Policy on Strategic Shareholdings



1. Looking back on the FY02/2024 (1)

Rx Business

- Mar. • Notification of approval for manufacturing and marketing approval of APOHIDE® Lotion 20% in Japan (Primary palmar hyperhidrosis treatment drug, development code: HP-5070)
- May. • Notification of Launch of APOHIDE® Lotion 20% in Japan (Primary palmar hyperhidrosis treatment drug)
- Jun. • Launch of APOHIDE® Lotion 20% in Japan (Primary palmar hyperhidrosis treatment drug)
- Jun. • Launch of TV commercial for primary palmar hyperhidrosis in Japan
- Jun. • “MOHRUS® TAPE 20mg” “MOHRUS® TAPE L40mg” Announcement of our wining 47th Kinoshita Prize for “Packaging Technology”
- Aug. • “MOHRUS® TAPE 20mg” “MOHRUS® TAPE L40mg” Announcement of our wining Optimum Packaging Award in Japan Packaging Contest 2023
- Sep. • Notification of the commencement of the Phase II clinical study of HP-6050 in Japan (a transdermal formulation for sedation)

OTC Business

- Mar. • Launch of “Feitas® Z Dicsas® ShippuF” 7 patches in Japan
- Apr. • Launch of “SALONPAS HOT®” 3 patches in Japan
- Apr. • Launch of Feitas® new TV Commercials in Japan
- Feb. • Launch of renewal “Feitas® 5.0” and “Feitas® 5.0 Large Size” in Japan
- Feb. • Launch of “Butenalock® Medical Soap Foot & Body” and “Butenalock® Medical Soap Foot & Body refillable” in Japan
- Feb. • Launch of new package “S-Cup®” and “Lacalut® new 5” in Japan

Mar.25 • Launch of new product “SALONPAS®” 90th Anniversary Limited Package Products



1. Looking back on the FY02/2024 (3)

Launch of Butenalock[®] Medical Soap Foot & Body



Butenalock[®] Medical Soap Foot & Body 300ml

- Bactericidal ingredients kill germs on feet and body
- Creamy and fine lather
- First of its kind in our company! Adoption of "Peelable film"



容器のボトルはバイオマスPET25%を使用しています。



Butenalock[®] Medical Soap Foot & Body refillable 250ml



この容器にはバイオマスPE 39%を使用しています。

■ Product Information : <https://www.hisamitsu.info/butena/>





1. Looking back on the FY02/2024 (4)

Launch of new package "S-Cup®" "Lacalut® new 5"

エスカップ S-CUP® 毎日の疲れを、自分で手当て。

薬用 ラカルト・ニュー5

「歯を支える歯ぐき」に
ギュッとひきしめ感！



Product Information : <https://www.s-cup.jp/>



Product Information : <https://www.hisamitsu.info/lacalut/>





1. Looking back on the FY02/2024 (5)

Launch of new product "Salonpas®" 90th Anniversary Limited Package Products

"Salonpas®" launched in 1934



"Salonpas®" 90th Anniversary Limited Package Products



"Salonpas®" series has undergone more than 50 improvements



Product Information :
<https://www.salonpas.jp/index.html>





1. Looking back on the FY02/2024 (6)

Others

- Mar. • The Minister of Economy, Trade and Industry Award at the 31st Global Environment Awards for the Kiyohara Industrial Park SmartEnergy Project
- Mar. • Became an official partner of TEAM JAPAN (topical analgesic anti-inflammatory drugs, muscle fatigue care products, and medical supporters)
- Mar. • JLPGA Step Up Tour Notice of the New Salonpas Ladies' Open to Be Held
- Mar. • Establishment of a new R&D center inside Shonan iPark
- Mar. • Notice regarding Revision of Earnings Forecast
- May. • Salonpas[®] Named the World's No. 1 OTC Topical Analgesic Patch Brand*1 for the Seventh Consecutive Year
- Jul. • Conclusion of a contract with SSP Co., Ltd. for the partial transfer of assets, related to S-Cup and Lacalut
- Jul. • Notice Regarding Company Split (Simplified Absorption-Type Split) with Hisamitsu Wellness Co., Ltd.
- Jul. • Notification Regarding Concerning the Decision of Matters Relating to Acquisition of Company's Own Shares
- Jul. • Notice regarding Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
- Jul. • Notice regarding Providing Relief Supplies in Response to the Torrential Rains from July 7, 2023
- Jul. • Notice regarding Determination of Details of Issuance of Stock Compensation Type Share Options (Stock Acquisition Rights)
- Aug. • Products to solve issues for living in Space and living on Earth "Odorleship[®]" Notification to be used in the International Space Station
- Sep. • Notification regarding Skin Care Cosmetics with Microneedle Technology
- Oct. • Announcement regarding completion of partial transfer of assets, related to S-Cup and Lacalut from SSP Co., Ltd.
- Dec. • Conclusion of Cooperation Agreement with Tosu City, Saga Prefecture, on the Provision of Disaster Shelter "Salonpas[®] Arena" to be offered as an evacuation center in times of disaster
- Dec. • Notice regarding Results and Completion of Acquisition of Treasury Shares
- Jan. • Notice regarding Revision of Earnings Forecast
- Jan. • Notice regarding Support for Disaster of the 2024 Noto Peninsula Earthquake
- Feb. • Hisamitsu Pharmaceutical Hot Heart Club decided to donate to support organizations in FY2023
- Feb. • Notice regarding Providing Relief Supplies in Disaster of the 2024 Noto Peninsula Earthquake
- Mar.11 • Notification of Completion of Construction of the New Research Laboratory "SAGA Global Research Center"
- Mar.29 • Expansion of domestic logistics system
- Apr.1 • Notice of Price Revision of products in Japan




1. Looking back on the FY02/2024 (7)

New Research Laboratory "SAGA Global Research Center"



SAGA Global Research Center

- Consolidation of domestic research bases into a single location to speed up research and development
- Establishment of "Joint Laboratory" to promote open innovation
- Obtained "ZEB Ready" certification*.



Joint Laboratory

*Building energy consumption
53% reduction

news release⇒ https://global.hisamitsu/pdf/news_release_E_240311.pdf






2. Promotion of Sustainability

**Hisamitsu Pharmaceutical Group's Materiality
(Priority Issues)**

**Contributing to local
communities**



Support for Disaster of the 2024 Noto Peninsula Earthquake

■ **A total of 10 million yen will be contributed through the Saga Branch of the Japanese Red Cross Society.**

We have decided to contribute relief money of 9 million yen and 1 million yen through the matching gift program called "Hisamitsu Pharmaceutical Co., Inc. Hot Heart Club" * to support victims of the 2024 Noto Peninsula Earthquake



news release⇒ https://global.hisamitsu/pdf/news_release_E_240111-2.pdf

■ Providing Relief Supplies

Free provision of relief supplies based on the "Agreement on Cooperation in Disaster Relief" signed with the Japanese Red Cross Society on January 31, 2020.



Jikabari[®]



Jikabari[®] Onkan Plus



Feitas[®] MEDICAL SUPPORTER
(for knee)



Feitas[®] MEDICAL SUPPORTER
(for low back)



news release⇒ https://www.hisamitsu.co.jp/company/pdf/news_release_240219.pdf

We sincerely pray for the earliest possible recovery of the disaster-stricken areas.



3. HX2025 Initiatives (1)



**7th Mid-Term
Management Policy**
～HX2025 (Hisamitsu Transformation 2025)～
September 17, 2021
President and CEO
NAKATOMI, Kazuhide

Hisamitsu Pharmaceutical Homepage
7th Mid-Term Management Policy
<https://global.hisamitsu/ir/medium-term.html>





3. HX2025 Initiatives (2)

		(First Year)	(Second Year)	(Third Year)	
	FY02/2021	FY02/2022	FY02/2023	FY02/2024	Targets at FY02/2026
Sales growth rate	114.5 billion yen	120.1 billion yen	128.3 billion yen (CAGR 5.9%)	141.7 billion yen (CAGR 7.4%)	CAGR 5.0% or more
Overseas Sales Ratio (Overseas Sales)	34.4% (39.3 billion yen)	34.5% (41.4 billion yen)	41.8% (53.6 billion yen)	42.8% (60.6 billion yen)	50.0% or more
ROE	3.7%	3.8% <ul style="list-style-type: none"> ✓ Repurchase of 2 million shares 	4.7% <ul style="list-style-type: none"> ✓ Dividend increase for 10 consecutive years ✓ Repurchase of 2 million shares 	5.4% <ul style="list-style-type: none"> ✓ Dividend increase for 11 consecutive years ✓ Repurchase of 2 million shares 	8.0% or more
Growth investment		<ul style="list-style-type: none"> ✓ Investment in GAIA Biomedicine, a bio-venture company ✓ Signed a license agreement with RaQualia Pharma Inc. 	<ul style="list-style-type: none"> ✓ Acquisition of Shares of AYM HD Co. ✓ Construction of New Research Center and Reorganization of Research Sites 	<ul style="list-style-type: none"> ✓ Completion of partial transfer of assets, related to S-Cup[®] and Lactalut[®] from SSP Co., Ltd 	Over 150 billion yen in five years



3. HX2025 Initiatives (3)

policy

Initiatives for FY 02/2025

① Expand

"Pillars of Growth"

Hisamitsu Group Growth Drivers
in the Five Years

- Nurture into a mainstay product (ZICTHORU[®] Tapes)
- Raise awareness of the disease and expand recognition (APOHIDE[®] Lotion)
- Launch products in Africa

② Exceed

"Overcoming Challenges."
~Beyond the barrier~

Overcoming Challenges and
Becoming the Next Generation's
Growth Driver

- Increase in overseas Rx sales (XELSTRYM[®])
- Completion of the domestic Phase II trial of HP-6050
- Expand the line of products using "Eco & Compact" packaging

③ Enhance

"Enhancing Functions"

Strengthening our
capabilities and Establish a
foundation for growth

- Launch of new package "S-Cup[®]" and "Lacalut[®]"
- Commencement of SAGA Global Research Center Operations
⇒ "Improved development speed and strengthened collaboration with the production department."



ZICTHORU[®] Tapes

APOHIDE[®] Lotion

Salonpas[®]

XELSTRYM[®]

Poke-Sip[®]

S-Cup[®]

Lacalut[®]



SAGA Global Research Center



4. Consolidated P&L (1) - Comparison with the previous period performance -

Unit:¥ Million

	Actual performance for FY02/2023	Actual performance for FY02/2024	Change	Percentage Change
Net sales	128,330	141,706	+13,375	+10.4%
CoGS	55,630	62,735	+7,104	+12.8%
as a % of sales	43.3%	44.3%		
SG&A costs	61,099	65,803	+4,703	+7.7%
Sales promotion costs	11,340	12,887	+1,546	+13.6%
Advertising costs	12,209	15,327	+3,118	+25.5%
R&D costs	9,785	8,614	-1,171	-12.0%
Others	27,763	28,973	+1,210	+4.4%
Operating profit	11,599	13,167	+1,567	+13.5%
Ordinary profit	16,051	19,649	+3,597	+22.4%
Net profit	11,742	13,969	+2,227	+19.0%
Exchange rate (¥/USD)	132.08	141.20		



4. Consolidated P&L (2) - Summary of Profit and Loss -

Unit:¥ Million

	Actual performance for FY02/2023	Actual performance for FY02/2024	Change	Main factor
Net sales	128,330	141,706	+13,375	
CoGS	55,630	62,735	+7,104	
as a % of sales	43.3%	44.3%		<ul style="list-style-type: none"> ▪ Increase in production costs ▪ Impact of the drug price revision in Japan. ▪ Change of sales mix.
SG&A costs	61,099	65,803	+4,703	
Sales promotion costs	11,340	12,887	+1,546	Aggressive investment to improve new products and brand value in Japan and overseas.
Advertising costs	12,209	15,327	+3,118	
R&D costs	9,785	8,614	-1,171	[FY02/2023]Expenses of Phase 3 clinical study of HP-5000.
Others	27,763	28,973	+1,210	Increase in activity expenses, depreciation
Operating profit	11,599	13,167	+1,567	
Non-operating balance	4,451	6,481	+2,030	Increase in interest income
Ordinary profit	16,051	19,649	+3,597	
Extraordinary balance	62	-462	-524	Impairment loss on idle assets
Net profit	11,742	13,969	+2,227	



5. Sales Results by Region

Unit:¥ Million

		Actual performance for FY02/23	Actual performance for FY02/24	change	percentage Change
Net sales		128,330	141,706	+13,375	+10.4%
Rx Business	Japan	53,135	54,437	+1,302	+2.5%
	Overseas	16,672	17,545	+873	+5.2%
	USA	11,567	11,530	-36	-0.3%
	Other regions	5,105	6,015	+909	+17.8%
OTC Business	Japan	18,373	23,337	+4,964	+27.0%
	Overseas	37,020	43,133	+6,113	+16.5%
	USA	16,727	19,506	+2,778	+16.6%
	Other regions	20,292	23,627	+3,334	+16.4%
Others	Japan	3,127	3,251	+123	+3.9%
Overseas Sales Ratio ^②		41.8%	42.8%		



6. Sales Results by Product (1) - Rx Business -

Unit:¥ Million

	Actual performance for FY02/24		
	Total	Japan	Overseas
Rx Business	71,983	54,437	17,545
Mohrus® Tape products	25,518	24,273	1,245
Zicthoru® Tapes	5,443	5,443	-
Haruropi® Tape	3,487	3,487	-
Fentos® Tapes	3,467	3,467	-
Mohrus® Pap products	3,582	3,582	-
Estrana® Tape	2,010	2,010	-
Allesaga® Tapes	403	403	-
Aphide® Lotion	984	984	-
Others	9,928	9,161	766
Vivelle-Dot® products	5,648	-	5,648
CombiPatch® products	7,430	1,623	5,806
Minivelle® products	2,591	-	2,591
Daytrana® products	684	-	684
Secuado®	740	-	740
Xelstry®	64	-	64

Change			Percentage Change		
Total	Japan	Overseas	Total	Japan	Overseas
+2,175	+1,302	+873	+3.1%	+2.5%	+5.2%
-3,372	-3,656	+284	-11.7%	-13.1%	+29.6%
+3,223	+3,223	-	+145.2%	+145.2%	-
+653	+653	-	+23.1%	+23.1%	-
-258	-258	-	-6.9%	-6.9%	-
-366	-366	-	-9.3%	-9.3%	-
-45	-45	-	-2.2%	-2.2%	-
+4	+4	-	+1.1%	+1.1%	-
+984	+984	-	-	-	-
+450	+636	-186	+4.7%	+7.5%	-19.6%
+194	-	+194	+3.6%	-	+3.6%
+707	+125	+581	+10.5%	+8.4%	+11.1%
+434	-	+434	+20.1%	-	+20.1%
-597	-	-597	-46.6%	-	-46.6%
+98	-	+98	+15.4%	-	+15.4%
+64	-	+64	-	-	-



6. Sales Results by Product (2) - OTC Business -

Unit: ¥ Million

	Actual performance for FY02/24		
	Total	Japan	Overseas
OTC Business	66,471	23,337	43,133
Salonpas® products	46,696	9,555	37,141
Feitas® products	3,854	3,790	64
Allegra® FX	4,201	4,201	-
Salonsip® products	2,793	1,497	1,295
Bye Bye Fever® products	3,710	306	3,403
Air® Salonpas® products	1,741	799	941
Butenalock® products	826	817	9
S-Cup® products	1,460	1,460	-
Others*	1,186	908	277

	Change			Percentage Change		
	Total	Japan	Overseas	Total	Japan	Overseas
	+11,077	+4,964	+6,113	+20.0%	+27.0%	+16.5%
	+7,509	+2,523	+4,985	+19.2%	+35.9%	+15.5%
	+133	+90	+42	+3.6%	+2.5%	+195.9%
	+940	+940	-	+28.8%	+28.8%	-
	-261	-328	+67	-8.5%	-18.0%	+5.5%
	+562	-65	+628	+17.9%	-17.6%	+22.6%
	+249	+79	+170	+16.8%	+11.1%	+22.1%
	+207	+199	+7	+33.5%	+32.4%	+388.4%
	+1,460	+1,460	-	-	-	-
	+274	+62	+212	+30.1%	+7.3%	+321.9%

*Includes amounts recorded as refund liabilities





Supplementary Data: Overseas OTC Business FY02/2024 New Products

New Release	Category	Region	Items	
Mar.2023- Feb.2024	OTC Business	North America	3	
		Asia	4	
	Others*	South America	1	
		Asia	4	
	OTC Business			7
	Others*			5
Total			12	

*Others: Medical devices, quasi-drugs, etc.






7. Trends of second-generation non-steroidal anti-inflammatory patch (Topical formulations) in Japan

Number of patches (Million)

Market trends on volume basis






8. Trends of Nonsteroidal Anti-inflammatory Drugs (Systemic formulations) Market Trend in Japan

Unit:¥ Million

Market trends on value basis





9. R&D Pipeline

	Stage	Theme	Target	Dosage Form	Characteristics	Next Step
1	Launched on Mar. 28th, FY24	OABLOK. EX PATCH (Neoxy.Tapes)	Asia	Patch	Overactive bladder	-
2	Launched on Mar. 28th, FY24	ALLESAGA. PATCH (Allesaga.Tapes)	Asia	Patch	Allergic rhinitis	-
3	Phase3	HP-5000	USA	Patch	Osteoarthritis of the knee	Under consideration
4	Phase2	HP-6050	JPN	Microneedle	Delirium, Psychomotor agitation and Irritability	Topline data in FY2024

Outlook for the FY02/2025



10. Forecast of Consolidated P&L

Unit:¥ Million

	Actual for FY02/24	Forecast for FY02/25	Change	Percentage Change
Net sales	141,706	152,000	+10,294	+7.3%
CoGS	62,735	67,300	+4,564	+7.3%
as a % of sales	44.3%	44.3%		
SG&A costs	65,803	70,200	+4,397	+6.7%
Sales promotion costs	12,887	13,900	+1,013	+7.9%
Advertising costs	15,327	15,800	+473	+3.1%
R&D costs	8,614	10,300	+1,685	+19.6%
Others	28,973	30,200	+1,226	+4.2%
Operating profit	13,167	14,500	+1,333	+10.1%
Ordinary profit	19,649	18,900	-749	-3.8%
Net profit	13,969	15,800	+1,830	+13.1%
Exchange rate (¥/USD)	141.2	141.00		



11. Forecast of Sales by Region

Unit:¥ Million

		Actual for FY02/24	Forecast for FY02/25	change	percentage Change
Net sales		141,706	152,000	+10,294	+7.3%
Rx Business	Japan	54,437	53,200	-1,238	-2.3%
	Overseas	17,545	19,700	+2,154	+12.3%
	USA	11,530	13,300	+1,769	+15.3%
	Other regions	6,015	6,400	+385	+6.4%
OTC Business	Japan	23,337	29,100	+5,762	+24.7%
	Overseas	43,133	46,600	+3,466	+8.0%
	USA	19,506	20,900	+1,394	+7.1%
	Other regions	23,627	25,700	+2,073	+8.8%
Others	Japan	3,251	3,400	+149	+4.6%
Overseas Sales Ratio ^②		42.8%	43.6%		



12. Forecast of Sales by Product (1) – Rx Business -

Unit:¥ Million

	Forecast for FY02/25		
	Total	Japan	Overseas
Rx Business	72,900	53,200	19,700
Mohrus® Tape products	21,200	19,900	1,300
Zicthoru® Tapes	7,900	7,900	-
Haruropi® Tape	4,100	4,100	-
Mohrus® Pap products	3,200	3,200	-
Fentos® Tape	2,900	2,900	-
Apohide® Lotion	2,400	2,400	-
Estrana® Tape	1,900	1,900	-
Others	10,100	9,700	400
CombiPatch® products	6,800	1,200	5,600
Vivelle-Dot® products	6,100	-	6,100
Minivelle® products	2,300	-	2,300
Xelstrym®	2,200	-	2,200
Secuado®	1,100	-	1,100
Daytrana® products	700	-	700

	Change			Percentage Change		
	Total	Japan	Overseas	Total	Japan	Overseas
	+916	-1,238	+2,154	+1.3%	-2.3%	+12.3%
Mohrus® Tape products	-4,319	-4,374	+55	-16.9%	-18.0%	+4.4%
Zicthoru® Tapes	+2,456	+2,456	-	+45.1%	+45.1%	-
Haruropi® Tape	+613	+613	-	+17.6%	+17.6%	-
Mohrus® Pap products	-382	-382	-	-10.7%	-10.7%	-
Fentos® Tape	-568	-568	-	-16.4%	-16.4%	-
Apohide® Lotion	+1,415	+1,415	-	+143.8%	+143.8%	-
Estrana® Tape	-110	-110	-	-5.5%	-5.5%	-
Others	-230	+135	-366	-2.2%	+1.4%	-47.8%
CombiPatch® products	-630	-424	-206	-8.5%	-26.1%	-3.6%
Vivelle-Dot® products	+451	-	+451	+8.0%	-	+8.0%
Minivelle® products	-291	-	-291	-11.2%	-	-11.2%
Xelstrym®	+2,136	-	+2,136	+3319.6%	-	+3319.6%
Secuado®	+359	-	+359	+48.5%	-	+48.5%
Daytrana® products	+15	-	+16	+2.3%	-	+2.4%



12. Forecast of Sales by Product (2) – OTC Business -

Unit:¥ Million


	Forecast for FY02/25			Change			Percentage Change		
	Total	Japan	Overseas	Total	Japan	Overseas	Total	Japan	Overseas
OTC Business	75,700	29,100	46,600	+9,228	+5,762	+3,466	+13.9%	+24.7%	+8.0%
Salonpas® products	51,300	11,300	40,000	+4,603	+1,745	+2,858	+9.9%	+18.3%	+7.7%
Feitas® products	4,400	4,300	100	+545	+509	+36	+14.1%	+13.4%	+56.1%
Bye Bye Fever® products	4,200	400	3,800	+490	+93	+396	+13.2%	+30.5%	+11.6%
S-Cup® products	4,100	4,100	-	+2,639	+2,639	-	+180.7%	+180.7%	-
Allegra® FX	3,800	3,800	-	-402	-402	-	-9.6%	-9.6%	-
Salonsip® products	3,300	1,900	1,400	+507	+402	+105	+18.1%	+26.9%	+8.1%
Air® Salonpas® products	2,000	900	1,100	+259	+100	+158	+14.9%	+12.6%	+16.8%
Butenalock® products	1,100	1,100	-	+274	+283	-	+33.1%	+34.6%	-
Others	1,500	1,300	200	+314	+392	-78	+26.4%	+43.1%	-28.1%





13. Forecast of Dividend (“SALONPAS®” 90th anniversary dividend)

➤ For the FY02/2025, the consolidated dividend payout ratio is predicted to be 43.8% and the annual payout is predicted to be ¥90.0. (*Predicted Mid-term dividend: ¥45.00)





14. Reduction of Policy on Strategic Shareholdings


< Policy on Strategic Shareholdings >

- In May every year, The Board of Directors evaluates whether it is reasonable to continue respective strategic shareholdings based on comprehensive consideration of qualitative verification such as the status of transactions and quantitative verification such as economic rationality based on benefits from transactions and dividends of each stock.
- Based on the results of the evaluation, the Company will reduce strategic shareholdings that it deems unreasonable to hold, through ongoing discussions with the issuing companies.

< Target for reducing Strategic Shareholdings >

**By the end of February 2025
Reduce policy Strategic Shareholdings to
less than 20% of consolidated net assets**

The cash generated will be used to
invest in future growth.



【Source】 Nikkei Stock Average

2022.02.
¥ 26,526.82

2023.02.
¥ 27,445.56

2024.02.
¥ 39,166.19



Our commitments originate from each individual's determination to "start something good for ecology (eco)!"

Hisamitsu Pharmaceutical has designed the "HELLO! eco!" mark as a symbol of its environmental activities, and products that have met the ecology standards that our company has established will display the "HELLO! eco!" mark sequentially.

Hisamitsu.

